315 related articles for article (PubMed ID: 29884444)
21. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?
Hatzimouratidis K
Expert Opin Investig Drugs; 2009 Mar; 18(3):245-54. PubMed ID: 19243276
[TBL] [Abstract][Full Text] [Related]
23. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Female Sexual Dysfunction and Erectile Dysfunction and Its Association with Lower Urinary Tract Symptoms in Women and Men Over 18 Years Old: Results From the COBaLT Study.
Bravo-Balado A; Trujillo CG; Caicedo JI; García S; Azuero J; Rondón M; Plata M
J Sex Med; 2021 Jun; 18(6):1065-1074. PubMed ID: 33992556
[TBL] [Abstract][Full Text] [Related]
25. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Campbell UB; Walker AM; Gaffney M; Petronis KR; Creanga D; Quinn S; Klein BE; Laties AM; Lewis M; Sharlip ID; Kolitsopoulos F; Klee BJ; Mo J; Reynolds RF
J Sex Med; 2015 Jan; 12(1):139-51. PubMed ID: 25358826
[TBL] [Abstract][Full Text] [Related]
26. Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.
Calogero AE; Burgio G; Condorelli RA; Cannarella R; La Vignera S
Aging Male; 2018 Dec; 21(4):272-280. PubMed ID: 29378485
[TBL] [Abstract][Full Text] [Related]
27. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.
Li WQ; Qureshi AA; Robinson KC; Han J
JAMA Intern Med; 2014 Jun; 174(6):964-70. PubMed ID: 24710960
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
Anderson SG; Hutchings DC; Woodward M; Rahimi K; Rutter MK; Kirby M; Hackett G; Trafford AW; Heald AH
Heart; 2016 Nov; 102(21):1750-1756. PubMed ID: 27465053
[TBL] [Abstract][Full Text] [Related]
29. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal Risk of Developing Cardiovascular Diseases in Patients With Erectile Dysfunction-Which Patients Deserve More Attention?
Pozzi E; Capogrosso P; Boeri L; Belladelli F; Baudo A; Schifano N; Abbate C; Dehò F; Montorsi F; Salonia A
J Sex Med; 2020 Aug; 17(8):1489-1494. PubMed ID: 32340919
[TBL] [Abstract][Full Text] [Related]
31. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
[TBL] [Abstract][Full Text] [Related]
32. Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.
Gillmeyer KR; Rinne ST; Glickman ME; Lee KM; Shao Q; Qian SX; Klings ES; Maron BA; Hanlon JT; Miller DR; Wiener RS
Circ Cardiovasc Qual Outcomes; 2020 May; 13(5):e005993. PubMed ID: 32393128
[TBL] [Abstract][Full Text] [Related]
33. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
Baydaroglu E; Eschwège P; Hubert J; El Osta R
Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
35. BPH/LUTS and ED: common pharmacological pathways for a common treatment.
Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R
J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
37. Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients.
Frederick LR; Cakir OO; Arora H; Helfand BT; McVary KT
J Sex Med; 2014 Oct; 11(10):2546-53. PubMed ID: 25059314
[TBL] [Abstract][Full Text] [Related]
38. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Lee M; Sharifi R
Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
[TBL] [Abstract][Full Text] [Related]
39. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
40. Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database.
Chappidi MR; Kates M; Sopko NA; Joice GA; Tosoian JJ; Pierorazio PM; Bivalacqua TJ
J Sex Med; 2017 Jun; 14(6):810-817. PubMed ID: 28460994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
